Drugs / zalunfiban
zalunfiban
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03844191 | Feb → Nov 2019 | coronary artery disorder | CeleCor Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04284995 | Jun → Nov 2020 | ST-elevation myocardial infarction, coronary artery disorder | CeleCor Therapeutics | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04825743 | Apr 2021 → May 2026 overdue | ST-elevation myocardial infarction | CeleCor Therapeutics | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-24 | CeleCor Therapeutics | Regulatory CeleCor completes submission of FDA New Drug Application for investigational heart-attack drug celecor.com ↗
CeleCor Therapeutics has submitted the final section of its New Drug Application for the company’s investigational heart-attack drug, zalunfiban (Disaggpro TM ), to the US Food and Drug Administration. |
| 2025-11-10 | CeleCor Therapeutics | Results Rapid zalunfiban treatment at 1st point of medical contact lowered risk of more severe heart damage in combination with other serious heart-attack complications celecor.com ↗
The study showed that rapid pre hospital treatment with zalunfiban improved and preserved blood flow to the heart until patients could be treated in the cardiac catheterization laboratory. |
| 2025-09-23 | CeleCor Therapeutics | Results Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results celecor.com ↗
CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug Disaggpro TM (zalunfiban) has shown positive primary efficacy and primary safety outcomes. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-24 | CeleCor Therapeutics | CeleCor completes submission of FDA New Drug Application for investigational heart-attack drug celecor.com ↗ |
| 2025-11-10 | CeleCor Therapeutics | Rapid zalunfiban treatment at 1st point of medical contact lowered risk of more severe heart damage in combination with other serious heart-attack complications celecor.com ↗ |
| 2025-09-23 | CeleCor Therapeutics | Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results celecor.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zalunfiban | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04825743 ↗ |
| Known as | RUC-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03844191 ↗ |
| Known as | RUC-4 acetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3114577 ↗ |
| Known as | ZALUNFIBAN ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3114577 ↗ |
| Action | Inhibit | “novel glycoprotein IIb/IIIa inhibitor designed for subcutaneous first point-of-care” PMID 32844723 ↗ Aug 2020 |
| Modality | Small molecule | “RUC-4: A Nonactivating Second-Generation Small-Molecule” PMID 32844723 ↗ Aug 2020 |
| Route | Subcutaneous | “single subcutaneous administration of RUC-4” NCT03844191 ↗ |